Spots Global Cancer Trial Database for inetetamab
Every month we try and update this database with for inetetamab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer | NCT06305702 | HER2-positive M... | inetetamab | 18 Years - | Liaoning Tumor Hospital & Institute | |
| Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer | NCT05016544 | Non-small Cell ... | inetetamab Pytotinib | 18 Years - | Sun Yat-sen University | |
| A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer | NCT06234137 | Breast Neoplasm... | Docetaxel Carboplatin Inetetamab Pyrotinib | 18 Years - 75 Years | First Affiliated Hospital of Wenzhou Medical University | |
| A Real-world Study of Inetetamab for First-line Treatment of MBC | NCT05980208 | Breast Cancer Real-world Stud... | Inetetamab | 18 Years - 75 Years | Hunan Cancer Hospital | |
| Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) | NCT05328440 | Breast Neoplasm... | Pyrotinib Malea... Dalpiciclib Ise... Inetetamab Fulvestrant | 18 Years - | Henan Cancer Hospital | |
| Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | NCT04681911 | Breast Cancer | Inetetamab Pyrotinib Capecitabine Gemcitabine Vinorelbine Carboplatin Albumin paclita... Eribulin | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway | NCT04736589 | Breast Cancer | Inetetamab Rapamycin Pyrotinib Chemotherapy | 18 Years - 85 Years | Peking Union Medical College | |
| Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) | NCT05328440 | Breast Neoplasm... | Pyrotinib Malea... Dalpiciclib Ise... Inetetamab Fulvestrant | 18 Years - | Henan Cancer Hospital | |
| Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer | NCT05291910 | Breast Cancer | Inetetamab Toripalimab Albumin-Bound P... | 18 Years - | ChineseAMS | |
| Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer | NCT05016544 | Non-small Cell ... | inetetamab Pytotinib | 18 Years - | Sun Yat-sen University | |
| Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer | NCT05823623 | Breast Cancer | Inetetamab Pyrotinib Oral Vinorelbin... | 18 Years - 85 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) | NCT05328440 | Breast Neoplasm... | Pyrotinib Malea... Dalpiciclib Ise... Inetetamab Fulvestrant | 18 Years - | Henan Cancer Hospital | |
| RWS of Inetetamab HER2 Positive Advanced Breast Cancer | NCT04963608 | HER2-positive A... | Inetetamab | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer | NCT05764941 | Breast Neoplasm... | Inetetamab Pyrotinib Vinorelbine | 18 Years - 80 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway | NCT04736589 | Breast Cancer | Inetetamab Rapamycin Pyrotinib Chemotherapy | 18 Years - 85 Years | Peking Union Medical College |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
